Stock RADL3 RAIA DROGASIL S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Raia Drogasil S.A.

Equities

RADL3

BRRADLACNOR0

Drug Retailers

Market Closed - Sao Paulo
Other stock markets
 21:07:57 28/06/2024 BST 		5-day change 1st Jan Change
25.68 BRL -3.24% Intraday chart for Raia Drogasil S.A. -0.47% -12.65%
05-08 Transcript : Raia Drogasil S.A., Q1 2024 Earnings Call, May 08, 2024
05-07 Raia Drogasil S.A. acquired remaining 15% stake in 4Bio Medicamentos S.A. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 36,800 41,301 40,026 39,085 50,403 44,044 - -
Enterprise Value (EV) 1 37,628 42,074 41,175 44,709 57,058 51,229 51,790 52,071
P/E ratio 67.9 x 71.4 x 49.3 x 39.4 x 46.3 x 33.6 x 24.9 x 20.3 x
Yield 0.57% 0.1% - - - 1.06% 1.62% 1.94%
Capitalization / Revenue 2.1 x 2.06 x 1.66 x 1.34 x 1.48 x 1.13 x 0.98 x 0.86 x
EV / Revenue 2.15 x 2.1 x 1.71 x 1.54 x 1.68 x 1.31 x 1.15 x 1.02 x
EV / EBITDA 28 x 29.4 x 22.8 x 19.8 x 21.9 x 12.4 x 10 x 9.24 x
EV / FCF 55.5 x 52.3 x 60.3 x 90.6 x 119 x 70.1 x 61.2 x 40.9 x
FCF Yield 1.8% 1.91% 1.66% 1.1% 0.84% 1.43% 1.63% 2.44%
Price to Book 9.14 x 9.47 x 8.56 x 7.32 x 8.46 x 6.36 x 5.55 x 4.84 x
Nbr of stocks (in thousands) 1,714,103 1,715,363 1,713,046 1,713,657 1,714,382 1,715,124 - -
Reference price 2 21.47 24.08 23.37 22.81 29.40 25.68 25.68 25.68
Announcement Date 19/02/20 09/03/21 22/02/22 07/03/23 05/03/24 - - -
1BRL in Million2BRL
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 17,503 20,067 24,127 29,067 33,974 39,133 44,867 51,173
EBITDA 1 1,344 1,429 1,807 2,262 2,603 4,141 5,175 5,637
EBIT 1 840.6 865.3 1,180 2,262 2,603 2,424 2,992 3,631
Operating Margin 4.8% 4.31% 4.89% 7.78% 7.66% 6.19% 6.67% 7.1%
Earnings before Tax (EBT) 1 649.1 743.2 1,065 1,193 1,312 1,704 2,317 2,902
Net income 1 542.9 579.3 815.2 996.1 1,151 1,305 1,713 2,113
Net margin 3.1% 2.89% 3.38% 3.43% 3.39% 3.33% 3.82% 4.13%
EPS 2 0.3161 0.3373 0.4739 0.5788 0.6356 0.7647 1.032 1.264
Free Cash Flow 1 678.6 804.2 683.1 493.5 480.7 731 846 1,272
FCF margin 3.88% 4.01% 2.83% 1.7% 1.42% 1.87% 1.89% 2.49%
FCF Conversion (EBITDA) 50.5% 56.27% 37.8% 21.81% 18.47% 17.65% 16.35% 22.56%
FCF Conversion (Net income) 124.99% 138.83% 83.8% 49.54% 41.77% 56.03% 49.4% 60.19%
Dividend per Share 2 0.1234 0.0231 - - - 0.2728 0.4149 0.4990
Announcement Date 19/02/20 09/03/21 22/02/22 07/03/23 05/03/24 - - -
1BRL in Million2BRL
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 6,474 6,563 7,179 7,490 7,836 7,931 9,025 9,288 8,924 9,100 9,728 9,980 10,248 10,406
EBITDA 448.1 388.4 727.5 546.8 599.4 563 767.6 658.1 614.5 679.9 - - - -
EBIT 1 276.9 220.7 555.7 369.9 599.4 374.3 573 453.8 614.5 563 710.3 609.2 618.4 657
Operating Margin 4.28% 3.36% 7.74% 4.94% 7.65% 4.72% 6.35% 4.89% 6.89% 6.19% 7.3% 6.1% 6.03% 6.31%
Earnings before Tax (EBT) 1 - 155.1 - 272.3 292.8 203.5 446.8 344.8 304.3 280.1 536.9 442.6 485.7 -
Net income 1 187.2 153.6 354.8 215.4 285.2 192.3 363.2 296.5 284.7 187.8 389.9 328.9 358.6 -
Net margin 2.89% 2.34% 4.94% 2.88% 3.64% 2.42% 4.02% 3.19% 3.19% 2.06% 4.01% 3.3% 3.5% -
EPS 2 0.1368 0.0812 0.2059 0.1252 0.1654 0.1099 0.2028 0.1586 0.1643 0.1126 0.2291 0.1937 0.2001 0.1900
Dividend per Share 2 - - - - - - - - - - 0.1177 - 0.1247 -
Announcement Date 22/02/22 03/05/22 29/07/22 31/10/22 07/03/23 02/05/23 08/08/23 31/10/23 05/03/24 07/05/24 - - - -
1BRL in Million2BRL
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 827 773 1,149 5,624 6,655 7,185 7,746 8,027
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.6157 x 0.5409 x 0.6358 x 2.486 x 2.556 x 1.735 x 1.497 x 1.424 x
Free Cash Flow 1 679 804 683 493 481 731 846 1,272
ROE (net income / shareholders' equity) 14.4% 13.8% 17.4% 19.9% 18.7% 21.3% 24.2% 26.2%
ROA (Net income/ Total Assets) 5.54% 4.61% 5.51% 6.23% 5.66% 7.37% 8.31% 9.29%
Assets 1 9,800 12,568 14,791 15,980 20,333 17,704 20,615 22,742
Book Value Per Share 2 2.350 2.540 2.730 3.120 3.470 4.040 4.630 5.300
Cash Flow per Share 2 0.5600 0.8600 0.9000 0.9800 1.080 1.490 1.690 2.410
Capex 1 287 673 867 1,189 1,305 1,232 1,345 1,372
Capex / Sales 1.64% 3.35% 3.6% 4.09% 3.84% 3.15% 3% 2.68%
Announcement Date 19/02/20 09/03/21 22/02/22 07/03/23 05/03/24 - - -
1BRL in Million2BRL
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Raia Drogasil S.A.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
25.68 BRL
Average target price
30.36 BRL
Spread / Average Target
+18.21%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Retail - Drugs without Grocery

1st Jan change Capi.
RAIA DROGASIL S.A. Stock Raia Drogasil S.A.
-12.65% 7.93B
AIN HOLDINGS INC. Stock Ain Holdings Inc.
+33.84% 1.3B
QOL HOLDINGS CO., LTD. Stock Qol Holdings Co., Ltd.
-9.90% 346M
NIHON CHOUZAI CO.,LTD. Stock NIHON CHOUZAI Co.,Ltd.
+6.86% 278M
SALUS, LJUBLJANA, D. D. Stock SALUS, Ljubljana, d. d.
+9.44% 222M
PETMED EXPRESS, INC. Stock PetMed Express, Inc.
-46.43% 80.61M
GREEN CROSS HEALTH LIMITED Stock Green Cross Health Limited
-34.86% 62.09M
MEDICAL IKKOU GROUP CO.,LTD. Stock Medical Ikkou Group Co.,Ltd.
+26.51% 60.97M
Retail - Drugs without Grocery
  1. Stock Market
  2. Equities
  3. RADL3 Stock
  4. Financials Raia Drogasil S.A.